TransMedics is facing allegations of fraud, organ trafficking, and unethical practices that have triggered shareholder ...

Shares of organ transplant innovator TransMedics Group (NASDAQ: TMDX) fell 15.7% through Thursday trading, according to data ...

Group addressed what we believe are inaccurate and misleading claims made in a short-seller report issued by Scorpion ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ:TMDX). Such ...

Scorpion Capital accuses TransMedics of fraudulent practices, kickbacks, and racketeering, setting a price target of $0.00. TransMedics denies the claims, stating the allegations aim to manipulate ...

NEW YORK CITY, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Scorpion Capital has assigned a target price of $0 to TransMedics stock, suggesting the firm believes the company’s alleged misconduct poses an existential threat. Hagens Berman’s ...

What is this about: On January 10, 2025, Scorpion Capital issued a report about TransMedics. In this report, Scorpion Capital stated that in “20 years of shorting, TransMedics is the most extreme and ...

The law firm of Kirby McInerney LLP is investigating potential claims against TransMedics Group, Inc. (“TransMedics” or the“Company”) (NASDAQ:TMDX). The investigation concerns whether TransMedics ...

ANDOVER, Mass., Jan. 13, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...

Scorpion Capital has assigned a target price of $0 to TransMedics stock, suggesting the firm believes the company's alleged misconduct poses an existential threat. Hagens Berman's Investigation of ...

Shares of TransMedics, Group Inc. (NASDAQ: TMDX) suffered a sharp decline over the past two trading days following the release of a ...